The acquired assets include the brand, the current healthcare business and existing customer relationships. Through its Diversey Care business, Sealed Air has had a long standing exclusive, global relationship with Virox and this new arrangement will enhance Diversey Care’s marketing of Virox’s proprietary Accelerated Hydrogen Peroxide(R) (AHP(R)) technology. In addition to increased focus on healthcare surface cleaning and disinfection applications, Diversey Care continues to provide all the benefits of AHP to the broader institutional markets like Education, Government, Facility Management, Retail and Food Service.
“We see a unique opportunity to leverage Virox’s patented technology and Professional and Technical Services (PTS) model around the world to deliver thought leadership in the cleaning and disinfecting arena,” said Ilham Kadri, President of Sealed Air’s Diversey Care Division. “Their PTS model leveraged with our sales coverage, application expertise, and global distribution will create an environment for the success of ourAHP-based solutions in the Oxivir(R) brand globally.”
AHP is a patented, synergistic blend of commonly used, safe ingredients, that when combined with low levels of hydrogen peroxide dramatically increase its disinfecting and cleaning ability. It provides the unique benefits of speed and efficacy, while being gentle on people, surfaces and the environment.
Virox CEO, Randy Pilon states, “Virox has a long standing relationship with Diversey Care and our combined healthcare business now puts Diversey in a leading position for knowledge-based solutions in surface disinfection in the healthcare sector in Canada. The plan is to replicate this success in the United States and become the infection prevention resource to healthcare professionals so that all the sectors supported by Diversey Care will feel confident in choosing their infection prevention solutions.”
Financial terms of the transaction were not disclosed. Sealed Air does not expect the transaction to be material to its consolidated financial position or results of operations.
Virox, founded in 1998 is headquartered in Ontario, Canada and is solely focused on the use of Hydrogen Peroxide as a sustainable, effective antimicrobial solution for hands, surfaces and devices, displacing legacy chemistries that are largely ineffective against targeted pathogens and can be harsh to the user and the environment. Virox has 7 global patents issued, with as many pending, and licenses the portfolio to global leaders in infection prevention across a variety of sectors including consumer, institutional, dental, animal health, agriculture and food processing.